PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Dr. Subramanian, Vaccine R&D at Merck to Speak at Protein Expression Conference, October 24-25 in San Diego - Shyamsundar Subramanian, Principal Scientist of Vaccine R&D at Merck to Speak on “Innovative Solutions to Recombinant Vaccine Expression Challenges” at GTC’s Protein Expression, Purification & Characterization Conference on October 24-25
Dr. Subramanian, Vaccine R&D at Merck to Speak at Protein Expression Conference, October 24-25 in San Diego

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/09/12 - Shyamsundar Subramanian, Principal Scientist of Vaccine R&D at Merck to Speak on “Innovative Solutions to Recombinant Vaccine Expression Challenges” at GTC’s Protein Expression, Purification & Characterization Conference on October 24-25.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The diverse nature of vaccines, even if one excludes live/inactivated viral vaccines, requires a search for the right expression platform early in the development cycle. In Dr. Subramanian’s presentation, case studies on two different vaccine candidates will be discussed:
1. An enveloped VLP vaccine candidate against a tropical viral diseases where transient mammalian expression was successful, but could not be translated to stable constitutive mammalian expression.
2. A tetravalent protein vaccine candidate against a nosocomial bacterial infection that was based on toxins that were highly cytotoxic to higher eukaryotic cell types.

These case studies will reveal that initial expression challenges can be overcome using creative strategies, but require early investment in the expression system screening and optimization.

Benefits of this talk include:
• What is the current approach to vaccine development, especially in the expression screening and optimization space?
• What are the expression challenges to recombinant vaccine production?
• What are some of the approaches to solve expression challenges?
• What is the future outlook for recombinant vaccines?

Dr. Shyamsundar Subramanian currently leads development for multiple viral and bacterial vaccine projects at Merck. & Co. He has responsibility from expression screening to identify cell substrates through process development, scale-up, and cGMP manufacture of clinical supplies. He has created an expression screening group within the Merck vaccines organization, and has successfully identified appropriate substrates and developed manufacturing processes for many novel vaccine candidates (recombinant protein, VLP, virus). In his current role, Dr. Subramanian is overseeing the introduction of a microcarrier-based bioreactor platform for live viral vaccines and insect cells for recombinant vaccine antigens for the Merck human vaccines portfolio.

The Protein Expression, Purification & Characterization Conference brings together experts from biotech, pharma, academia and the public sector to discuss the issues, challenges and opportunities in the field of protein expression and purification as it relates to therapeutic development. Topics of discussions will include novel expression platforms and systems, protein optimization, new purification methods, protein analytical tools, process development, scale-up and manufacturability.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Dr. Subramanian, Vaccine R&D at Merck to Speak at Protein Expression Conference, October 24-25 in San Diego

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)